20:14 , Oct 5, 2018 |  BC Week In Review  |  Financial News

New IPO filings include NGM, Arog, Gamida

Three biotechs filed late Sept. 28 to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South...
12:22 , Oct 1, 2018 |  BC Extra  |  Financial News

New IPO filings include NGM, Arog, Gamida

Three more biotechs filed late Friday to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South...
19:49 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

NGM reports Phase II data for NGM282 in primary sclerosing cholangitis

NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) reported additional data from a Phase II trial in 62 primary sclerosing cholangitis (PSC) patients with elevated alkaline phosphatase levels showing that once-daily subcutaneous 3 mg NGM282 significantly...
19:32 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

NGM's NGM282 meets in Phase II data for NASH

NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) reported data from a single-blind Phase II trial in 19 non-alcoholic steatohepatitis (NASH) patients showing that once-daily subcutaneous 3 mg NGM282 met the primary endpoint of reducing absolute...
03:08 , Dec 14, 2017 |  BC Innovations  |  Translation in Brief

Ghrelin’s LEAP forward

NGM and MedImmune researchers have discovered a liver peptide, LEAP2, that is a natural antagonist of the metabolic target ghrelin. The peptide could serve as a new handle for either boosting or dampening ghrelin signaling...
21:05 , Apr 27, 2017 |  BC Week In Review  |  Clinical News

NGM282: Additional Ph II data

Additional data from a double-blind, international Phase II trial in 82 NASH patients with stage 1-3 liver fibrosis and ≥8% liver fat content showed that once-daily 3 and 6 mg subcutaneous NGM282 for 12 weeks...
02:34 , Apr 24, 2017 |  BC Extra  |  Clinical News

NGM, BMS add to NASH data

Newly released data from a Phase II study of NGM282 from NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) to treat non-alcoholic steatohepatitis showed that 3 and 6 mg doses of the candidate increased LDL levels...
23:33 , Apr 14, 2017 |  BioCentury  |  Product Development

New endpoints in NASH

Data on mid-stage NASH candidates to be presented at the European Association for the Study of the Liver’s International Liver Congress this month won’t enable solid comparisons with each other or with more advanced programs....
18:42 , Apr 7, 2017 |  BC Week In Review  |  Clinical News

NGM282: Ph II data

Data from 82 evaluable NASH patients with stage 1-3 liver fibrosis and ≥8% liver fat content in a double-blind, international Phase II trial showed that once-daily 3 and 6 mg subcutaneous NGM282 reduced absolute liver...
22:41 , Apr 5, 2017 |  BC Extra  |  Clinical News

New NASH readouts for NGM, Bristol

New data showed that fibroblast growth factor (FGF) analogs from NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) and Bristol-Myers Squibb Co. (NYSE:BMY) each reduced liver fat in separate Phase II studies to treat non-alcoholic steatohepatitis....